advertisement
Abstract #6874 Published in IGR 4-1
Intraocular pressure-lowering effects of latanoprost and brimonidine therapy in patients with open-angle glaucoma or ocular hypertension: a randomized observer-masked multicenter study
Kampik A; Arias-Puente A; O'Brart DP; Vuori ML; European Latanoprost Study Group; The European Latanoprost Study GroupJournal of Glaucoma 2002; 11: 90-96
PURPOSE: To compare the effect of treatment with latanoprost or brimonidine on intraocular pressure in patients with glaucoma or ocular hypertension and intraocular pressure (IOP) inadequately controlled by monotherapy or dual therapy. PATIENTS AND METHODS: Three hundred and seventy-nine patients with primary open-angle glaucoma or ocular hypertension were recruited for this six-month prospective, randomized, observer-masked multicenter study involving 30 eye clinics. All patients were receiving monotherapy or dual therapy that did not adequately control IOP. After appropriate washout periods, patients were randomized to treatment with latanoprost once daily or brimonidine twice daily. The main outcome measure was change in mean diurnal IOP after six months of treatment compared with baseline. RESULTS: Of the 379 randomized patients, 375 were included in the intent-to-treat analysis. From an overall baseline mean intraocular pressure of 25.0 mmHg, latanoprost monotherapy reduced mean diurnal IOP by 7.1 ± 3.3 mmHg (mean ± SD, p < 0.001), whereas brimonidine monotherapy yielded an IOP reduction of 5.2 ± 3.5 mmHg (p < 0.001). This 1.9 mmHg difference in IOP reduction was significantly in favor of latanoprost (p < 0.001). Ocular allergy (p < 0.001) and systemic side-effects (p = 0.005) were reported significantly less frequently by latanoprost-treated patients compared with brimonidine-treated patients. CONCLUSIONS: Both latanoprost and brimonidine reduced IOP in patients with glaucoma or ocular hypertension after six months of treatment. However, latanoprost once daily was significantly more effective than brimonidine twice daily in reducing mean diurnal IOP. Latanoprost was better tolerated with less frequently occurring ocular allergy and systemic side-effects.
Dr. A. Kampik, Department of Ophthalmology, Ludwigs-Maximilians University, Munich, Germany
Classification:
11.3.3 Apraclonidine, brimonidine (Part of: 11 Medical treatment > 11.3 Adrenergic drugs)
11.4 Prostaglandins (Part of: 11 Medical treatment)
